Per Morten Sandset Japan-UiO cooperation within health and care research status and opportunities

Size: px
Start display at page:

Download "Per Morten Sandset Japan-UiO cooperation within health and care research status and opportunities"

Transcription

1 Per Morten Sandset Japan-UiO cooperation within health and care research status and opportunities

2 Japan-UiO cooperation within health and care Brief presentation of the University of Oslo (UiO) Ongoing collaboration(s) between Japan and UiO Some examples and opportunities

3 staff

4 Worlds 62nd best university Shanghai Ranking of World Universities

5

6

7

8

9 UiO:Life Science Strategy convergence The planned life science building Strengthen quality and interaction in research Solve grand challenges, value creation & international competitiveness A new arena for collaboration in research, education and innovation Recruit, educate and develop talents Promote innovation in the life sciences related to environment and health and closer collaboration with hospitals and businesses A resource for the whole Oslo region

10 The life science building 2024 Norway s largest university building Department of Chemistry School of Pharmacy Centre for Molecular Medicine Norway (NCMM) & interdisciplinary life science research groups

11 Japan-UiO cooperation within health and care Brief presentation of the University of Oslo Ongoing collaboration(s) between Japan and UiO Some examples and opportunities

12 UiO Japan overall research performance

13 Japan-UiO cooperation within health and care Brief presentation of the University of Oslo Ongoing collaboration(s) between Japan and UiO Some examples and opportunities Physics and radiosotopes Life science School of dentistry

14 Radiumhospitalet National Cancer Hospital: Planned proton therapy center in Oslo Radiotherapy building (2006) New clinic Research building (2008) Proton therapy center

15 Research topics preclinical research Radiation Biology effects of protons compared to conventional X-rays Tumor and normal tissue effects Combinatory treatment (e.g. chemotherapy or immunotherapy + proton therapy) Biomarker-based treatment outcome prediction Radiation and medical physics Detector development New principles for quality assurance New proton beam control systems Basic radiation physics

16 Dementia research with PET From development of new radiolabelling reactions To clinical trials with a radiotracer for dementia

17

18 Flavours of Pluripotent Stem Cells

19 Why do we need hepatocytes? Toxicity Screening Disease Modelling Bio-artificial Liver Malaria & HCV Transplantation

20 Interaction (consultant basis) on development of a Norwegian clinical biobank of allogeneic ips cells Norwegian Center for Stem Cell Research (prof J Glover) Norwegian Bone Marrow Donor Registry Kyoto University Center for ips Cell Research and Application (CiRA)

21 Hybrid Technology Hub (Director and Prof. Stefan Krauss) Center of Excellence htpp:// Department of Molecular Medicine, Institute of Basic Medical Sciences The goal: cross-disciplinary international Hybrid Technology Hub is to develop organ on a chip platform that reproduces core functionalities of the human body. allows real time data acquisition upon exposure to therapeutic reagents current focus is on energy metabolism regulating organs. Main research fields: Microfluidic carrier platform Sensor systems and imaging Organoid systems Drug testing Bioinformatics Ethics The Hybrid Technology Hub Centre of Excellence is divided into 11 research groups, that will contribute to one or more of the centre's six research topics.

22 Faculty of Mathematics and Natural Sciences Faculty of Medicine Faculty of Social Sciences Faculty of Humanities (IFIKK) Museum of Cultural History Interdisciplinary research groups convergence environments Combining natural and social sciences to understand and manage global anthropogenic toxicants (AnthroTOX) Epigenetics and bioethics of human embryonic development Programmable Cell-like Compartments Comparative immunology of fish and humans (COMPARE) Organ on a chip and nano-device (CHIP) Personalised cancer therapies (PERCATHE) The genetic history of Eastern Eurasia (ARCH-GEN)

23 School of Dentistry Biomaterials Cell Engineering Division, RIKEN BioResource Center, Tsukuba, Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki Surgery/imaging Nihon University, Tokyo (K Honda) Jikei University, Tokyo (K Hayashi) Osaka Dental University (Y Yotsui)

24 Health Information Systems Program HISP a global action research network initiated in collaboration with University of Western Cape in 1994 funded by Norad. DHIS 2, District Health Information Software, is an open source software for reporting, analysis and dissemination of data for all health programs Shared and integrated data warehouse for essential health data: information for action Aggregate, events, and patient data Generic and generative platform - supports a wide range of uses also beyond the health sector Financed and endorsed by all Global Health agencies, WHO, Norad, CDC, PEPFAR, Unicef, Gates Foundation, USAID, Global Fund, GAVI DHIS2 used in 88 countries in the Global South Dec 2017: WHO collaborating Centre

25 HISP - action oriented multidisciplinary research Strengthening national health information systems Collaborating with Ministries of Health Participatory design (Scandinavian tradition) Action Research: Building knowledge on implementing HIS while building systems on the ground through partnerships. PhD school: 48 PhDs graduated International Masters programs in South Africa, Mozambique, Malawi, Tanzania, Ethiopia, Sri Lanka total 400 graduated

26 Scientia Fellows postdoctoral mobility program EU, Horizon 2020 COFUND, Marie Curie Program 125 postdoc fellows Incoming postdoctoral fellowship (12-36 months) Outgoing postdoctoral fellowship (12-36 months) Project period:

27 The overall objectives A program worldwide in the area of Health Life Sciences Provide excellent research environments and infrastructure Provide interaction between academia and health technology industry/clusters with SMEs. Provide a training program designed to maximize the career prospects of the researchers by the development of translational, multidisciplinary research skills along with transferable skills including entrepreneurship, dissemination and management.

28 Scientia Fellows

Promoting collaboration: Strategies and programs within health research and innovation

Promoting collaboration: Strategies and programs within health research and innovation Promoting collaboration: Strategies and programs within health research and innovation Anne K Fahlvik, PhD, Executive director Mari K Nes, PhD, Special Adviser The Research Council of Norway The Research

More information

Realizing the Future that Regenerative Medicine Will Open

Realizing the Future that Regenerative Medicine Will Open 470 Hitachi Review Vol. 65 (2016), No. 9 Featured Articles Realizing the Future that Regenerative Medicine Will Open Shizu Takeda, Ph.D. OVERVIEW: Regenerative medicine is an innovative approach to medicine

More information

TOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS

TOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS TOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS William S. Dalton, PhD, MD CEO, M2Gen & Director, Personalized Medicine Institute, Moffitt Cancer Center JULY 15, 2013 MOFFITT CANCER CENTER

More information

Why Culture Matters in Cancer Research

Why Culture Matters in Cancer Research Why Culture Matters in Cancer Research Edward L. Trimble, MD, MPH National Cancer Institute Government-University-Industry Research Roundtable, July 29-31, 2013 Need for international research collaboration

More information

INF5750 March HISP Health Information Systems Programme. Ola Hodne Titlestad

INF5750 March HISP Health Information Systems Programme. Ola Hodne Titlestad INF5750 March 3-2008 HISP Health Information Systems Programme Ola Hodne Titlestad olati@ifi.uio.no Overview of this lecture Introduction to HISP Health information systems (basics) The DHIS software -

More information

REIMAGINING DRUG DEVELOPMENT:

REIMAGINING DRUG DEVELOPMENT: Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY

More information

Stem cell and cell therapeutics research in Lithuania. Bernardas Morkunas Head of Business Development

Stem cell and cell therapeutics research in Lithuania. Bernardas Morkunas Head of Business Development Stem cell and cell therapeutics research in Lithuania Bernardas Morkunas Head of Business Development Lithuanian biotech Biotechnology is considered as one of 2014-2020 Smart Specialisation priority fields

More information

Parallel Workshops III International Cooperation in Education and Training. Chadamas Thuvasethakul NSTDA, Thailand 20 April 2018

Parallel Workshops III International Cooperation in Education and Training. Chadamas Thuvasethakul NSTDA, Thailand 20 April 2018 Parallel Workshops III International Cooperation in Education and Training Chadamas Thuvasethakul NSTDA, Thailand 20 April 2018 1 Thailand s National Biotechnology Policy Framework (2012-2021) Vision Green

More information

Translational Research

Translational Research Translational Research Paddy Johnston Chair, MRC Translational Research Overview Group October 2012 Translational Research Strategy and its delivery To accelerate patient benefit and increase economic

More information

Relative cost of hepatocytes

Relative cost of hepatocytes Relative cost of hepatocytes - WORKPACKAGE 8 PROGENITOR CELLS FOR BIO- ARTIFICIAL LIVER UNEW, Charité, SCS StemCellSystems WP2 System design and medical device regulatory requirements WP7 Communications,

More information

World s 1 st Clinical Trial with Allogeneic ipsc-derived Therapeutic Product (Cynata Therapeutics) Physician Led Study Using ipscs for

World s 1 st Clinical Trial with Allogeneic ipsc-derived Therapeutic Product (Cynata Therapeutics) Physician Led Study Using ipscs for Table of Contents SCOPE AND METHODOLOGY... 8 Market Definition... 8 Market Scope... 8 Market Stakeholders... 9 Research Methodology... 10 Secondary and Primary Research Methodology... 10 Market Size Estimation

More information

The Health Information Systems Programme (HISP) Dealing with complexity in health information systems in developing countries

The Health Information Systems Programme (HISP) Dealing with complexity in health information systems in developing countries The Health Information Systems Programme (HISP) Dealing with complexity in health information systems in developing countries Outline What is HISP The evolving DHIS2 software Challenges with HIS in developing

More information

EU support for Health Research from FP6 to FP7

EU support for Health Research from FP6 to FP7 EU support for Health Research from FP6 to FP7 Stéphane Hogan Head of Biotechnology Unit Directorate for Health Research DG Research - European Commission Valencia - 15 September 2006 EU research programmes

More information

Health Information Systems Programme. Professor Kristin Braa Department of Informatics, University of Oslo

Health Information Systems Programme. Professor Kristin Braa Department of Informatics, University of Oslo Health Information Systems Programme Professor Kristin Braa kbraa@ifi.uio.no Department of Informatics, University of Oslo Health Information Systems Program District Health Information System - DHIS 2

More information

The Integrated Biomedical Sciences Graduate Program

The Integrated Biomedical Sciences Graduate Program The Integrated Biomedical Sciences Graduate Program at the university of notre dame Cutting-edge biomedical research and training that transcends traditional departmental and disciplinary boundaries to

More information

EMA s role & responsibility for the development of modern/advanced therapies

EMA s role & responsibility for the development of modern/advanced therapies EMA s role & responsibility for the development of modern/advanced therapies Agenda Current regulatory picture Overall Regulatory framework New Committee at EMA Current Activities & Challenges Egbert Flory

More information

Pharmacy. i3l PHARMACY BACHELOR PROGRAM. The architect of drugs. Improving the Quality of Life

Pharmacy. i3l PHARMACY BACHELOR PROGRAM. The architect of drugs. Improving the Quality of Life i3l PHARMACY BACHELOR PROGRAM The architect of drugs Improving the Quality of Life Pharmacy Message From the Head of Study Program Pharmaceutical products are essential to support various human health

More information

Our job today Enlist you to help us cross the Translational Divide between the lab bench and the patient s bedside Demonstrate that this will

Our job today Enlist you to help us cross the Translational Divide between the lab bench and the patient s bedside Demonstrate that this will Bench Bedside Our job today Enlist you to help us cross the Translational Divide between the lab bench and the patient s bedside Demonstrate that this will be done in our Kimmel Cancer Center at Hopkins,

More information

Fostering Convergent Scientific Research and Industry Engagement in a University Setting: Challenges and Strategies

Fostering Convergent Scientific Research and Industry Engagement in a University Setting: Challenges and Strategies Fostering Convergent Scientific Research and Industry Engagement in a University Setting: Challenges and Strategies Colin Duckett, Ph.D. Professor, Departments of Pathology & Internal Medicine Director,

More information

TRANSLATIONAL RESEARCH IN RARE AND NEUROMUSCULAR DISEASES - WHY DATA SHARING MATTERS. H a n n s Lochmüller, Newcastle University

TRANSLATIONAL RESEARCH IN RARE AND NEUROMUSCULAR DISEASES - WHY DATA SHARING MATTERS. H a n n s Lochmüller, Newcastle University TRANSLATIONAL RESEARCH IN RARE AND NEUROMUSCULAR DISEASES - WHY DATA SHARING MATTERS H a n n s Lochmüller, Newcastle University Addressing the translational pathway 2 Trials Gene identification/ pathophysiology

More information

HISP Health Information Systems Program DHIS District Health information Software Ongoing Open Source: application sw technologies

HISP Health Information Systems Program DHIS District Health information Software Ongoing Open Source: application sw technologies HISP Health Information Systems Program DHIS District Health information Software 1994 2007 Ongoing Open Source: application sw technologies Background South Africa: Started 1994/95 as a RDP project funded

More information

Current Japanese Regulation for Cell Therapy and NCC strategy

Current Japanese Regulation for Cell Therapy and NCC strategy Current Japanese Regulation for Cell Therapy and NCC strategy National Cancer Center Hospital Department of Medical Oncology Division of Cell and Gene Therapy Yuji Heike Today s topics 1)Current Regulation

More information

ORACLE OTTAWA REGION FOR ADVANCED CARDIOVASCULAR RESEARCH EXCELLENCE STRATEGIC DIRECTIONS

ORACLE OTTAWA REGION FOR ADVANCED CARDIOVASCULAR RESEARCH EXCELLENCE STRATEGIC DIRECTIONS ORACLE OTTAWA REGION FOR ADVANCED CARDIOVASCULAR RESEARCH EXCELLENCE STRATEGIC DIRECTIONS 2018-2024 ORACLE 2.0: Leading Globally, from Innovation to Impact P1 P2 NOTE FROM OUR LEADERS NOTE FROM VP RESEARCH,

More information

Vision, aims and strategies. Department of Immunology, Genetics and Pathology Uppsala University

Vision, aims and strategies. Department of Immunology, Genetics and Pathology Uppsala University Vision, aims and strategies Department of Immunology, Genetics and Pathology Uppsala University April19,2011 SCOPEOFACTIVITIESATIGP Research at the Department focuses on translational medicine through

More information

Centre for NanoHealth

Centre for NanoHealth Steve Conlan PhD An integrated collaborative base for businesses in Wales Director - Reproductive Biology & Cancer Research Institute of Life Science School of Medicine Unique interdisciplinary R&D environment,

More information

Protein research and bioinformatics

Protein research and bioinformatics Protein research and bioinformatics LauritzenConsulting Content and application Proteins are the fundamental building blocks of life. Research in Greater Copenhagen focuses on the significance of proteins

More information

Stem Cell Principle -

Stem Cell Principle - Effective Date: 31.10.2017 Doc ID: 20290214 Version: 1.0 Status: Approved Planned Effective Date: 31-Oct-2017 00:00 CET (Server Date) Stem Cell Principle - Rationale Research on human stem cells and their

More information

PROGRAMME T

PROGRAMME T BIOART Summer School Biomedical membranes and (bio)artificial organs 8-12 June 2015 Venue University of Twente Horstring Building Room N 109 PROGRAMME Contents Welcome to the BIOART Summer School-------------------------------

More information

Our Research Strategy

Our Research Strategy Our Research Strategy 2014-2017 Introduction Kidney Research UK has a 52-year legacy in funding excellent research into all aspects of kidney diseases and disorders. Each year over 3.7 million 1 new investments

More information

Research and Innovation in Drug Discovery and Diagnostics

Research and Innovation in Drug Discovery and Diagnostics INTERNATIONAL CONFERENCE Intellectual Property and Health Innovation Challenges for the future April 28, 2014, Athens, Greece Research and Innovation in Drug Discovery and Diagnostics Alexander Pintzas,

More information

SPECTArare as an innovative model of combining clinical research and care in an ERN. Denis Lacombe, MD, MSc EORTC, Director General Brussels, Belgium

SPECTArare as an innovative model of combining clinical research and care in an ERN. Denis Lacombe, MD, MSc EORTC, Director General Brussels, Belgium SPECTArare as an innovative model of combining clinical research and care in an ERN Denis Lacombe, MD, MSc EORTC, Director General Brussels, Belgium Contents The changing clinical research pathway How

More information

Konica Minolta to Acquire Invicro (US)

Konica Minolta to Acquire Invicro (US) Konica Minolta to Acquire Invicro (US) Acceleration of expansion of precision medicine business Offering new value for drug discovery and development in immuno-oncology and neurodegenerative disease September

More information

What IMI means for POLAND

What IMI means for POLAND What IMI means for POLAND Maciej Bagiński Gdansk University of Technology Deputy of Polish Delegate to IMI SRG History of calls 1 st call 15 projects (395 teams) 281 mln 2 nd call 8 projects (193 teams)

More information

Comparative Oncology Program

Comparative Oncology Program The Problem: Non-Integrated Cancer Drug Development A Solution: Integration of Informative Non-Clinical Models of Cancer With Clinical Drug Development Efforts Companion Animal Malignancies as Comparative

More information

Gene therapy. Findings by Alert

Gene therapy. Findings by Alert Gene therapy Published Mar 21, 2000 Version 1 Findings by Alert Research in gene therapy has increased dramatically during the past 15 years, particularly in the United States. The research has encompassed

More information

IRDiRC: International Rare Diseases Research Consortium

IRDiRC: International Rare Diseases Research Consortium IRDiRC: International Rare Diseases Research Consortium EuRenomics, NEUROMICS and RD-Connect Joint Kick-off Meeting Sitges, Spain, 25 January 2013 Dr. Iiro Eerola Scientific Project Officer Unit for Personalised

More information

Regulation of advanced blood cell therapies

Regulation of advanced blood cell therapies Regulation of advanced blood cell therapies www.pei.de Clinical trials using cell-based products Substantially manipulated cells and cells for non-homologous use Quality, safety and non-clinical aspects

More information

Nordic Trial Alliance Nordic Cooperation in Clinical Research

Nordic Trial Alliance Nordic Cooperation in Clinical Research Nordic Trial Alliance Nordic Cooperation in Clinical Research Mia Bengtström Nordic Trial Alliance Background Aim to strengthen clinical research in the Nordics Objective to contribute to sustainable Nordic

More information

The Life Innovation Policy of Japan and Activities of MEXT

The Life Innovation Policy of Japan and Activities of MEXT The Life Innovation Policy of Japan and Activities of MEXT November 2011 Hiroyuki KAMAI Deputy Director, Life Sciences Division Research Promotion Bureau Ministry of Education, Culture, Sports, Science

More information

Linking high education and research to promote young researchers international mobility in agrosciences. Prof. Stéphane GUILBERT Agreenium

Linking high education and research to promote young researchers international mobility in agrosciences. Prof. Stéphane GUILBERT Agreenium Workshop on improving the mobility of researchers between Europe and BRIC countries SFIC-SGHRM Brussels, 12 June 2012 Linking high education and research to promote young researchers international mobility

More information

Successful Academia-Pharma Collaboration Drug Discovery and Clinical Development

Successful Academia-Pharma Collaboration Drug Discovery and Clinical Development Successful Academia-Pharma Collaboration Drug Discovery and Clinical Development Toshio MIYATA Tohoku University Graduate School of Medicine United Centers for Advanced Research and Translational Medicine

More information

Building the Europe of Knowledge

Building the Europe of Knowledge Building the Europe of Knowledge 7 th Framework Programme 2007-2013 Nanotechnology! All information preliminary! FP7 1. Capacities: Infrastructures 2. People: Erasmus, Marie-Curie 3. Ideas: ERC 4. Cooperation:

More information

European Regenerative Medicine Firms & Their Strategic Approaches. Michael Morrison University of York

European Regenerative Medicine Firms & Their Strategic Approaches. Michael Morrison University of York European Regenerative Medicine Firms & Their Strategic Approaches Michael Morrison University of York OVERVIEW Creating the European RM Universe of firms Characterizing the European RM Universe Strategic

More information

Nanotechnology and Advanced Materials for more effective Healthcare

Nanotechnology and Advanced Materials for more effective Healthcare Nanotechnology and Advanced Materials for more effective Healthcare This challenge taps into the potential of nanotechnologies and advanced materials to enable more effective therapies and diagnostics

More information

Molecular Diagnostics

Molecular Diagnostics Molecular Diagnostics Part II: Regulations, Markets & Companies By Prof. K. K. Jain MD, FRACS, FFPM Jain PharmaBiotech Basel, Switzerland May 2018 A Jain PharmaBiotech Report A U T H O R ' S B I O G R

More information

From IMI to IMI2 new models of collaborative research. Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014

From IMI to IMI2 new models of collaborative research. Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014 From IMI to IMI2 new models of collaborative research Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014 What is IMI and how does it work? Innovative Medicines Initiative: Joining Forces in the

More information

The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Catalog Addendum

The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Catalog Addendum The University of Texas MD Anderson Cancer Center UTHealth 2016-2018 Catalog Addendum GSBS 2016-18 Catalog Addendum Table of Contents School Name Change... 1 Areas of Research Concentration Changes...

More information

Stem cells for therapeutic use

Stem cells for therapeutic use Transition to an industrial scale of human stem cell production for therapeutic use by Bruno JARRY, Jean-François STOLTZ and Raymond ARDAILLOU on behalf of a working group joining Academy of Technologies

More information

Trans NCI Initiatives Role of imaging as an enabling technology

Trans NCI Initiatives Role of imaging as an enabling technology Oncology Co-Clinical Research Resources (Us) to Develop Best Practices for Quantitative (QI) in Mouse Models A Trans-NCI Initiative Larry Clarke, PhD, Branch Chief, CIP DCTD AAPM Meeting July th 0 Trans

More information

Stem Cells: Introduction and Prospects in Regenerative Medicine.

Stem Cells: Introduction and Prospects in Regenerative Medicine. Stem Cells: Introduction and Prospects in Regenerative Medicine www.gothamgazette.com/.../stemcell/stem_cell.jpg Ode to a Stem Cell, Part II by VCW There once was stem cell stuck in the hood Dividing endlessly,

More information

Healthy Ageing. From Basic Science to Clinical Applications and New Business. Jan Sikkema Center for Development and Innovation June 16, 2016

Healthy Ageing. From Basic Science to Clinical Applications and New Business. Jan Sikkema Center for Development and Innovation June 16, 2016 Healthy Ageing From Basic Science to Clinical Applications and New Business Jan Sikkema Center for Development and Innovation June 16, 2016 Groningen Broad Research University 11 faculties > 30.000 students

More information

UKRO 2011 Annual Conference

UKRO 2011 Annual Conference UKRO 2011 Annual Conference Newcastle, 8 July Vanessa Debiais-Sainton Policy Officer DG Education, Culture, Multilingualism and Youth Unit C3, Marie Curie Actions AGENDA Objectives of Marie Curie Actions

More information

Career Growth Areas in Physiology / Pharmacology

Career Growth Areas in Physiology / Pharmacology Career Growth Areas in Physiology / Pharmacology Magdalena Alonso-Galicia, PhD Pharmacology Department Forest Research Institute, Inc. Jersey City, NJ 1 Career Growth Areas in BioPharma n Pharmaceutical

More information

About Taipei Medical University. Jan. 2018

About Taipei Medical University. Jan. 2018 About Taipei Medical University Jan. 2018 Outline 1. Current Status 2. Specific Strategies 3. Conclusion 2 TMU Organization 624 faculty members, 6,112 students Student-faculty ratio: 9.0 3 Vision & Goal

More information

MRC Stratified Medicine Initiative

MRC Stratified Medicine Initiative MRC Stratified Medicine Initiative Jonathan Pearce Medical Research Council, Translational Programme Manager Pharmacogenetics and Stratified Medicine Network Conference : 14 th January 2015 Stratified

More information

Nordic Common Strengths and Future Potential in the Field of Personalised Medicine

Nordic Common Strengths and Future Potential in the Field of Personalised Medicine Nordic Common Strengths and Future Potential in the Field of Personalised Medicine NOS-M Workshop 23rd November 2016 Stockholm Waterfront Johan Nilsson Coordinator Medicine and Health Swedish Research

More information

Overview of the Luxembourg biomedical and health research ecosystem FNR FRANK GLOD LUXCOR HEALTH EVENT MONDAY 19 JUNE 2017

Overview of the Luxembourg biomedical and health research ecosystem FNR FRANK GLOD LUXCOR HEALTH EVENT MONDAY 19 JUNE 2017 FNR Overview of the Luxembourg biomedical and health research ecosystem FRANK GLOD LUXCOR HEALTH EVENT MONDAY 19 JUNE 2017 Research in Luxembourg Luxembourg : a young research location Creating structures

More information

Is a Career in the. Pharmaceutical. Check out our online Student Center to find out more:

Is a Career in the. Pharmaceutical. Check out our online Student Center to find out more: Is a Career in the Pharmaceutical Sciences Right for Me? Check out our online Student Center to find out more: www.aaps.org/forstudents How Do I Know If a Career in the Pharmaceutical Sciences is Right

More information

University of Athens - Medical School. pmedgr. The Greek Research Infrastructure for Personalized Medicine

University of Athens - Medical School. pmedgr. The Greek Research Infrastructure for Personalized Medicine University of Athens - Medical School pmedgr The Greek Research Infrastructure for Personalized Medicine - George Kollias - Professor of Experimental Physiology, Medical School, University of Athens President

More information

Delivering the NIHR Central Commissioning Facility

Delivering the NIHR Central Commissioning Facility Delivering the NIHR Central Commissioning Facility About the NIHR The National Institute for Health Research is funded through the Department of Health to improve the health and wealth of the nation through

More information

E&T objectives in evolving pharma business models. Magda Chlebus Director Science Policy Brussels, 2 March 2015

E&T objectives in evolving pharma business models. Magda Chlebus Director Science Policy Brussels, 2 March 2015 E&T objectives in evolving pharma business models Magda Chlebus Director Science Policy Brussels, 2 March 2015 Education adapted to demand? Declining number of students choosing science Education still

More information

EE 45X Biomedical Nanotechnology. Course Proposal

EE 45X Biomedical Nanotechnology. Course Proposal EE 45X Biomedical Nanotechnology 1 Introduction Jie Chen ECERF W6-019 492-9820 jchen@ece.ualberta.ca Oct. 15, 2008 The purpose of this document is to propose a new course in the area of Biomedical Nanotechnology

More information

Basic Information. I.1 If your company performs biotechnology research and development, uses a. The Categories of Biotechnology Applications.

Basic Information. I.1 If your company performs biotechnology research and development, uses a. The Categories of Biotechnology Applications. APPENDIX 2 SURVEY QUESTIONNAIRE Part I. Basic Information I.1 If your company performs biotechnology research and development, uses a biotechnology process in manufacturing, or produces research tools,

More information

Data Warehouse Systems at the German Centers for Health Research (DZG)

Data Warehouse Systems at the German Centers for Health Research (DZG) Data Warehouse Systems at the German Centers for Health Research (DZG) Roland Eils 26.10.16 Roland Eils The German Centers for Health Research è Fighting major disease challenges è Translational Research,

More information

- OMICS IN PERSONALISED MEDICINE

- OMICS IN PERSONALISED MEDICINE SUMMARY REPORT - OMICS IN PERSONALISED MEDICINE Workshop to explore the role of -omics in the development of personalised medicine European Commission, DG Research - Brussels, 29-30 April 2010 Page 2 Summary

More information

Education Critical to Stem Cell Therapy Pipeline

Education Critical to Stem Cell Therapy Pipeline June 2016 Education Critical to Stem Cell Therapy Pipeline Don L. Gibbons Senior Science and Education Communication Officer ABOUT California Institute for Regenerative Medicine (CIRM) CIRM is California

More information

Personalized. Health in Canada

Personalized. Health in Canada Personalized Health in Canada Canadian Institutes of Health Research Personalized Medicine Signature Initiative 2010-2013 0 Dr. Morag Park CIHR Institute of Cancer Research Dr. Paul Lasko CIHR Institute

More information

The Seventh Framework Programme ( )

The Seventh Framework Programme ( ) The Seventh Framework Programme (2007-2013) Opportunities for Cardiovascular Research 1 Octavi Quintana Trias, MD, MPH Director Health DG Research - European Commission Octavi.Quintana-Trias@ec.europa.eu

More information

Horizon 2020 funding opportunities for Regenerative Medicine ( ) Rudolf Fryček, PhD.

Horizon 2020 funding opportunities for Regenerative Medicine ( ) Rudolf Fryček, PhD. Horizon 2020 funding opportunities for Regenerative Medicine (2018-2020) Rudolf Fryček, PhD. Disclaimer: Any information mentioned is preliminary only, always consult the official documents. 1 Outline

More information

Innovative Medicines Initiative - the story so far

Innovative Medicines Initiative - the story so far Innovative Medicines Initiative - the story so far Ruxandra Draghia-Akli MD PhD Director Health, Research & DG Health Research at a Crossroads Are Public-Private Partnerships the Way Forward? European

More information

Regulatory Perspectives of Japan

Regulatory Perspectives of Japan International Alliance for Biological Standardization (IABS) Challenge Toward Sound Scientific Regulation of Cell Therapy Products at Kyoto International Conference Center, Kyoto, Japan Regulatory Perspectives

More information

Topic: Genome-Environment Interactions in Inflammatory Skin Disease

Topic: Genome-Environment Interactions in Inflammatory Skin Disease Topic: Genome-Environment Interactions in Inflammatory Skin Disease All information regarding future IMI Call topics is indicative and subject to change. Final information about future IMI Calls will be

More information

Early Stage Researcher (ESR) position for research on Pre-clinical studies on neurotransmitter replacement in the basal ganglia for PD and HD

Early Stage Researcher (ESR) position for research on Pre-clinical studies on neurotransmitter replacement in the basal ganglia for PD and HD Early Stage Researcher (ESR) position for research on Pre-clinical studies on neurotransmitter replacement in the basal ganglia for PD and HD Applications are invited from suitably qualified candidates

More information

Regulation of Cell and Gene Therapy Products in Canada

Regulation of Cell and Gene Therapy Products in Canada Regulation of Cell and Gene Therapy Products in Canada Canadian Blood and Bone Marrow Transplant Group June 8, 2018 Nadine Kolas, PhD Senior Policy Analyst Blood, Cells, Tissues and Organs Biologics and

More information

Cardiac Safety Research Consortium Annual Meeting. Future Areas of Focus & Opportunities 18 October 2016

Cardiac Safety Research Consortium Annual Meeting. Future Areas of Focus & Opportunities 18 October 2016 Cardiac Safety Research Consortium Annual Meeting Future Areas of Focus & Opportunities 18 October 2016 CSRC MISSION To advance scientific knowledge on cardiac safety for new and existing medical products

More information

The Irish Biomarker Network - Inaugural Workshop Improved Translation of Biomarkers to the Clinic

The Irish Biomarker Network - Inaugural Workshop Improved Translation of Biomarkers to the Clinic The Irish Biomarker Network - Inaugural Workshop Improved Translation of Biomarkers to the Clinic 1 The Irish Biomarker Network -Inaugural Workshop Improved Translation of Biomarkers to the Clinic Overview

More information

European Induced Pluripotent Stem Cell Bank

European Induced Pluripotent Stem Cell Bank European Induced Pluripotent Stem Cell Bank Background Researchers are looking for ways to validate pathways using human data. ips cells are one approach to this. ips research and banking is fragmented

More information

SSPPS STRATEGIC PLAN. Pharmacy Education, Pharmaceutical Sciences Research, Clinical Pharmacy Practice. April 30, Overview

SSPPS STRATEGIC PLAN. Pharmacy Education, Pharmaceutical Sciences Research, Clinical Pharmacy Practice. April 30, Overview SSPPS STRATEGIC PLAN Pharmacy Education, Pharmaceutical Sciences Research, Clinical Pharmacy Practice April 30, 2012 Overview Here we present the 2012-2017 strategic plan for the Skaggs School of Pharmacy

More information

The Present State and Future Perspective of Biomedical Engineering in Japan

The Present State and Future Perspective of Biomedical Engineering in Japan The Present State and Future Perspective of Biomedical Engineering in Japan Shunsuke Sato (Osaka University, Graduate School of Engineering Science) Fumihiko Kajiya (Okayama University, Graduate School

More information

The National Institutes of Health ICs: mission and funding strategies

The National Institutes of Health ICs: mission and funding strategies The National Institutes of Health ICs: mission and funding strategies Perry Kirkham, Ph.D. Office of the Vice President for Research E-mail: pkirkham@purdue.edu Phone: 63645 NIH Workshop topics and dates

More information

IMI: A Public Private Partnership Funder

IMI: A Public Private Partnership Funder IMI: A Public Private Partnership Funder 25-26 July 2011, European Medicines Agency Transatlantic workshop: Drug-related Progressive Multifocal Leukoencephalopathy The Innovative Medicines Initiative (IMI):

More information

Biomedical Engineering

Biomedical Engineering GRIGORE T. POPA UNIVERSITY OF MEDICINE AND PHARMACY IASI, ROMANIA Faculty of Medical Bioengineering Biomedical Engineering MASTER s degree education excellence in medical education since 1879 If life is

More information

National Health Research Institutes

National Health Research Institutes National Health Research Institutes October 2008 History The founding of the National Health Research Institutes (NHRI) was first proposed in 1988 by members of Academia Sinica. In 1994 a preparatory committee

More information

Week 1: Discovery Biology Basic knowledge and tools used in Research and Development

Week 1: Discovery Biology Basic knowledge and tools used in Research and Development Downing - Keio Summer School 2018 Healthcare and Biotechnology Course Outline page 1 Strand A: Healthcare and Biotechnology Course Outline This course aims to provide an overview of the current challenges

More information

2. Purpose and Mission of the icems

2. Purpose and Mission of the icems Research Center Project Host institution name Kyoto University Head of host institution Professor Kazuo Oike, Ph. D., President of Kyoto University Title of center project Center name Institute for Integrated

More information

Innovative collaboration system on ips cell technologies

Innovative collaboration system on ips cell technologies Innovative collaboration system on ips cell technologies Kyoto University Founded in 1897 National Innovation System, Competition and Cooperation June 11, 2009 Yutaka Teranishi, Ph.D. Kyoto University

More information

The International Consortium for Personalised Medicine

The International Consortium for Personalised Medicine The International Consortium for Personalised Medicine Mairead O Driscoll Alliance for Biomedical Research in Europe, 8 November 2017 Personalised Medicine A definition Characterisation of individuals

More information

Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development

Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration

More information

ADAMAS UNIVERSITY FACULTY OF SCIENCE - DEPARTMENT OF BIOTECHNOLOGY BACHELOR OF SCIENCE (Honours) SEMESTER - I

ADAMAS UNIVERSITY FACULTY OF SCIENCE - DEPARTMENT OF BIOTECHNOLOGY BACHELOR OF SCIENCE (Honours) SEMESTER - I NEW CHOICE BASED CREDIT SYSTEM (TOTAL CREDIT = 22+22+28+28+26+26 = 152) Type of the Paper Paper Code ADAMAS UNIVERSITY FACULTY OF SCIENCE - DEPARTMENT OF BIOTECHNOLOGY SEMESTER - I / Brief Contents I BT1201

More information

REMEDiE Project London 7-8 May 2009 European Policies and Priorities for Stem Cell Research

REMEDiE Project London 7-8 May 2009 European Policies and Priorities for Stem Cell Research REMEDiE Project London 7-8 May 2009 European Policies and Priorities for Stem Cell Research Charles Kessler European Commission DG Research, Health Directorate Outline of presentation Main features of

More information

ITN Proposal Evaluation: Advice for a Successful Application

ITN Proposal Evaluation: Advice for a Successful Application ITN Proposal Evaluation: Advice for a Successful Application Christos A. Panagiotidis, Ph.D Professor of Cell & Molecular Biology School of Pharmacy, Faculty of Health Sciences Aristotle University of

More information

DBT-IIT Workshop. IIT Bombay Presentation. by Prof. Dulal Panda

DBT-IIT Workshop. IIT Bombay Presentation. by Prof. Dulal Panda DBT-IIT Workshop IIT Bombay Presentation by Prof. Dulal Panda 1 Research & Development 2 Faculty involved in Bio-research 15% faculty of institute actively involved in bio-research A wide-spectrum from

More information

Asterand Bioscience Strategic Alliances

Asterand Bioscience Strategic Alliances Asterand Bioscience Strategic Alliances Excellence through partnership www.asterandbio.com WHY ASTERAND BIOSCIENCE Asterand Bioscience has a well-established human tissue heritage, having been formed in

More information

IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager

IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager Introducing IMI2: Vienna 16 July 2014 The way in which pharmaceutical companies develop new medicines

More information

Regulatory frameworks of regenerative medicines and products review in Japan

Regulatory frameworks of regenerative medicines and products review in Japan Regulatory frameworks of regenerative medicines and products review in Japan August 27th, 2018 Kenji KUROIWA Deputy Director, Medical Devices Evaluation Division Ministry of Health, Labour and Welfare,

More information

Missouri Regional Life Sciences Summit March 9, 2010 The Institute for Advancing Medical Innovation Stepping into the future of drug discovery, delivery and biomedical engineering G. Sitta Sittampalam,

More information

Innovative Medicines Initiative

Innovative Medicines Initiative Innovative Medicines Initiative EMA - EBE Regulatory Conference on ATMPs Salah-Dine Chibout, Novartis Global Head Discovery & Investigative Safety/ Global Head Preclinical Safety Therapeutic Areas IMI

More information

Regulatory Support to EU Research

Regulatory Support to EU Research Regulatory Support to EU Research OPEN INFO DAY Horizon 2020 'Health, demographic change and wellbeing Friday, 8 December 2017 Brussels Presented by Marisa Papaluca Senior Scientific Advisor, Scientific

More information

REQUEST FOR APPLICATIONS. MMRF Immunotherapy Networks of Excellence

REQUEST FOR APPLICATIONS. MMRF Immunotherapy Networks of Excellence REQUEST FOR APPLICATIONS MMRF Immunotherapy Networks of Excellence June 29, 2017 1. FUNDING OPPORTUNITY DESCRIPTION Purpose/Overall Goal: The Multiple Myeloma Research Foundation (MMRF) is issuing this

More information